Mather Group, Llc. Regeneron Pharmaceuticals, Inc. Transaction History

Mather Group, Llc.

$7.74 Billion
Q3 2024

A detailed history of Mather Group, Llc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Mather Group, Llc. holds 972 shares of REGN stock, worth $682,917. This represents 0.01% of its overall portfolio holdings.

Number of Shares

972

Previous 1,144 15.03%

Holding current value

$682,917

Previous $1.2 Million 15.06%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 07, 2024	SELL	$1024.09 - $1201.76 $176,143 - $206,702	-172 Reduced 15.03%	972 $1.02 Million
Q2 2024 Jul 08, 2024	BUY	$883.2 - $1071.19 $83,904 - $101,763	95 Added 9.06%	1,144 $1.2 Million
Q1 2024 Apr 08, 2024	BUY	$902.69 - $993.35 $3,610 - $3,973	4 Added 0.38%	1,049 $1.01 Million
Q4 2023 Feb 05, 2024	SELL	$775.18 - $881.7 $10,852 - $12,343	-14 Reduced 1.32%	1,045 $917,000
Q3 2023 Nov 13, 2023	BUY	$692.45 - $844.37 $87,941 - $107,234	127 Added 13.63%	1,059 $871,000
Q2 2023 Aug 08, 2023	BUY	$700.03 - $830.35 $392,016 - $464,996	560 Added 150.54%	932 $669,000
Q1 2023 May 09, 2023	BUY	$680.49 - $826.97 $25,858 - $31,424	38 Added 11.38%	372 $305,000
Q4 2022 Mar 10, 2023	BUY	$705.89 - $766.39 $7,764 - $8,430	11 Added 3.41%	334 $240,000
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $185,392 - $233,955	323 New	323 $222,000
Q4 2021 Feb 15, 2022	SELL	$543.48 - $670.97 $259,239 - $320,052	-477 Closed	0 $0
Q3 2021 Nov 04, 2021	BUY	$574.03 - $680.96 $273,812 - $324,817	477 New	477 $289,000

Others Institutions Holding REGN

# of Institutions

1,534

Shares Held

83.6M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $75.3B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mather Group, Llc., based on Form 13F filings with the SEC.

News

Stay updated on Mather Group, Llc. with notifications on news.

Account